CN110958880B - 固体分散制剂 - Google Patents

固体分散制剂 Download PDF

Info

Publication number
CN110958880B
CN110958880B CN201780091536.0A CN201780091536A CN110958880B CN 110958880 B CN110958880 B CN 110958880B CN 201780091536 A CN201780091536 A CN 201780091536A CN 110958880 B CN110958880 B CN 110958880B
Authority
CN
China
Prior art keywords
solid dispersion
spray
compound
pharmaceutically acceptable
dried solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780091536.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110958880A (zh
Inventor
许明珠
林助强
金其新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan East Sunshine Medicine Research And Development Co ltd
Original Assignee
Dongguan East Sunshine Medicine Research And Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan East Sunshine Medicine Research And Development Co ltd filed Critical Dongguan East Sunshine Medicine Research And Development Co ltd
Publication of CN110958880A publication Critical patent/CN110958880A/zh
Application granted granted Critical
Publication of CN110958880B publication Critical patent/CN110958880B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780091536.0A 2017-05-30 2017-05-30 固体分散制剂 Active CN110958880B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/035000 WO2018222172A1 (fr) 2017-05-30 2017-05-30 Formulation de dispersion de solide

Publications (2)

Publication Number Publication Date
CN110958880A CN110958880A (zh) 2020-04-03
CN110958880B true CN110958880B (zh) 2023-08-08

Family

ID=64456246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780091536.0A Active CN110958880B (zh) 2017-05-30 2017-05-30 固体分散制剂

Country Status (2)

Country Link
CN (1) CN110958880B (fr)
WO (1) WO2018222172A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4323362A1 (fr) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020698A (zh) * 2009-09-15 2011-04-20 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103272234A (zh) * 2006-03-20 2013-09-04 沃泰克斯药物股份有限公司 药物组合物
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
DK2477980T3 (en) * 2009-09-15 2016-09-12 Taigen Biotechnology Co Ltd HCV protease inhibitors
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CN105884779B (zh) * 2015-02-13 2018-06-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020698A (zh) * 2009-09-15 2011-04-20 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂

Also Published As

Publication number Publication date
WO2018222172A1 (fr) 2018-12-06
CN110958880A (zh) 2020-04-03

Similar Documents

Publication Publication Date Title
TWI666020B (zh) 固體分散製劑
US8686026B2 (en) Solid compositions
CA3114454C (fr) Dispersion solide de n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
AU2009300866B2 (en) Pharmaceutical formulation 514
US20200261479A1 (en) Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
WO2015152433A1 (fr) Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation
EA015715B1 (ru) Твердая дисперсия, фармацевтическая композиция, включающая такую дисперсию, способ ее получения и применение для предотвращения и лечения заболеваний, связанных с бензодиазепиновыми рецепторами периферического типа
US20230065636A1 (en) Compositions of substituted pyrazolopyrimidines and uses thereof
WO2013089479A1 (fr) Dispersion solide contenant du célécoxib et son procédé de préparation
US20170368031A1 (en) Solid dispersion formulations of antiviral compounds
MXPA06000370A (es) Dispersion solida de tacrolimus.
CN110958880B (zh) 固体分散制剂
TW202227067A (zh) Ｍａｌｔ１抑制劑之無定形形式及其配製物
US20160346289A1 (en) Fixed-Dose Combinations of Antiviral Compounds
US11872224B2 (en) Amorphous solid dispersion formulation
WO2022095913A1 (fr) Formulation solide
CN117337170A (zh) 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯七蕃-74-甲酰胺的药物剂型
US20150322047A1 (en) Crystal Forms
JPH11335302A (ja) 安定な医薬組成物
US20160339074A1 (en) Pharmaceutical composition of selective hcv ns3/4a inhibitors
CN106456612A (zh) 经口给药用医药组合物
WO2022090953A1 (fr) Dispersion solide de chlorhydrate de ponatinib et son procédé de préparation
CA3235680A1 (fr) Compositions comprenant un inhibiteur d'erk
US20190202812A1 (en) Crystal Forms
NZ733835A (en) Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant